OPIOID INHIBITION OF NICOTINE-INDUCED CA-45(2+)-UPTAKE INTO CULTURED BOVINE ADRENAL-MEDULLARY CELLS

被引:15
作者
BUNN, SJ
DUNKLEY, PR
机构
[1] The Neuroscience Group, Faculty of Medicine, University of Newcastle, Shortland
关键词
D O I
10.1016/0006-2952(91)90071-C
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The ability of a number of opioid agonists and antagonists to affect nicotine-induced Ca-45(2+)-uptake into cultured bovine adrenal medullary cells has been investigated. High (10-mu-M) concentrations of the opioid agonist bremazocine produced a significant inhibition of nicotine-induced Ca-45(2+)-uptake throughout the 15 min time course examined. The opioid subtype-selectivity of this inhibition was investigated; mu and delta selective agonists produced only minor effects whereas the kappa selective agonist U50-488H and the endogenous opioid peptides dynorphin(1-13) and metorphamide almost abolished nicotine-induced Ca-45(2+)-uptake. The U50-488H inhibition was significant at 10 nM concentrations with an IC50 of approximately 1-mu-M. U50-488H inhibition could not be reversed or reduced by the opioid antagonists naxolone, diprenophine or Mr2266. Furthermore, Mr2266 and its optical isomer Mr2267 also produced marked inhibition of Ca-45(2+)-uptake. The inhibition was specific to nicotine-induced Ca-45(2+)-uptake in that a similar level of uptake evoked by potassium depolarization was unaffected by high concentrations of U50-488H. These data indicate that opioid inhibition of nicotine-induced Ca-45(2+)-uptake does not involve classical, stereospecific opioid receptors and suggests the involvement of a pharmacologically distinct opioid recognition site. It is speculated that this may be associated with the nicotine receptor-ionophore complex.
引用
收藏
页码:715 / 722
页数:8
相关论文
共 45 条
[41]   DIFFERENTIAL RELEASE OF ENKEPHALIN AND ENKEPHALIN-CONTAINING PEPTIDES FROM PERFUSED CAT ADRENAL-GLANDS [J].
VINDROLA, O ;
ASE, A ;
FINKIELMAN, S ;
NAHMOD, VE .
JOURNAL OF NEUROCHEMISTRY, 1988, 50 (02) :424-430
[42]  
VIVEROS OH, 1979, MOL PHARMACOL, V16, P1101
[43]  
VonVoigtlander P F, 1987, Adv Exp Med Biol, V221, P345
[44]  
VONVOIGTLANDER PF, 1983, J PHARMACOL EXP THER, V224, P7
[45]  
WILSON SP, 1982, J NEUROSCI, V2, P1150